Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
3.270
+0.210 (6.86%)
May 27, 2026, 10:57 AM EDT - Market open
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
108
Market Cap
233.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Atrium Therapeutics | 36.68M |
| Voyager Therapeutics | 36.49M |
| Keros Therapeutics | 33.18M |
| Tonix Pharmaceuticals Holding | 17.56M |
| MediWound | 16.96M |
| Caribou Biosciences | 11.20M |
| Whitehawk Therapeutics | 7.15M |
NKTX News
- 9 days ago - Nkarta price target lowered to $9 from $25 at Evercore ISI - TheFly
- 14 days ago - Nkarta reports Q1 EPS (37c), consensus (37c) - TheFly
- 14 days ago - Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 14 days ago - Nkarta Earnings release: Q1 2026 - Filings
- 14 days ago - Nkarta Quarterly report: Q1 2026 - Filings
- 14 days ago - Nkarta Slides: Corporate presentation - Filings
- 4 weeks ago - Nkarta Proxy statement: Proxy filing - Filings
- 4 weeks ago - Nkarta Proxy statement: Proxy filing - Filings